Merck's Cornerstone Cancer Drug at ASCO: Key Insights

Key Takeaways

• KEYNOTE-942 five-year RFS HR was 0.51 (49% risk reduction) and DMFS HR was 0.411 (59% risk reduction) versus pembrolizumab monotherapy.
• Median planned follow-up reached 60.3 months (range 50.5–76.4) at the December 15, 2025 cutoff.
• Merck said more than 100 ASCO 2026 abstracts spanned over 25 cancer types, reinforcing Keytruda’s franchise breadth.
• OS trend favored the combination (HR 0.471) but remains exploratory; Phase 3 confirmation is still outstanding.

What Keytruda data did Merck highlight at ASCO 2026?

Merck’s ASCO 2026 portfolio release framed Keytruda as the durable commercial and clinical center of its oncology franchise, with new long-term data across early- and late-stage settings. The headline melanoma readout was the five-year analysis of KEYNOTE-942, evaluating intismeran autogene (mRNA-4157/V940) with Keytruda after complete resection of high-risk stage III/IV melanoma.

According to the joint Moderna–Merck June 1, 2026 release, the combination continued to prolong recurrence-free survival, the study’s primary endpoint, and improved distant metastasis-free survival. The companies said findings would be presented at ASCO and published simultaneously in the Journal of Clinical Oncology.

How large was the recurrence-free survival benefit?

In KEYNOTE-942, 157 patients were randomized 2:1 to intismeran plus pembrolizumab (n=107) or pembrolizumab alone (n=50). Patients in the combination arm received nine doses of intramuscular intismeran 1 mg every three weeks plus 18 doses of intravenous pembrolizumab 200 mg every three weeks.

At five years, the combination reduced recurrence or death risk by 49% (HR 0.51; 95% CI 0.294–0.887) and distant metastasis or death by 59% (HR 0.411; 95% CI 0.200–0.843). Five-year RFS rates reported in secondary coverage of the abstract were about 68.8% versus 49.1%. The exploratory overall survival HR was 0.471 (95% CI 0.165–1.345), with few events. The trial is registered as NCT03897881.

What else in Merck’s ASCO slate supports the franchise?

Merck’s broader ASCO preview listed more than 100 abstracts across over 25 tumor types. Beyond KEYNOTE-942 (Abstract 9500), the company flagged final KEYNOTE-522 analysis in high-risk early-stage triple-negative breast cancer and progression-free survival data from ASCENT-04/KEYNOTE-D19 combining Keytruda with Trodelvy in previously untreated PD-L1-positive metastatic TNBC.

That breadth matters commercially. Keytruda’s competitive moat is no longer a single metastatic indication; it is multi-indication evidence density and combination optionality. Investors should separate Phase 2b melanoma durability from registrational breast-cancer packages when modeling label expansion risk.

Primary framing of the full slate appears in Merck’s ASCO 2026 oncology portfolio announcement.

What does KEYNOTE-942 mean for competitors?

If Phase 3 confirms the RFS and DMFS signals, individualized mRNA neoantigen therapy could become a differentiated adjuvant layer on top of PD-1 blockade rather than a replacement for Keytruda. That would extend Merck’s checkpoint franchise into a personalized vaccine adjunct market while giving Moderna a high-visibility oncology beachhead.

Rivals with adjuvant melanoma assets will need longer follow-up and cleaner OS stories. For payers, a personalized manufacturing workflow raises cost and logistics questions that a standard intravenous pembrolizumab regimen does not. Commercial models should price cold-chain and turnaround-time friction, not only hazard ratios.

What remains unproven?

KEYNOTE-942 is not Phase 3. Sample size is modest, OS confidence intervals are wide, and five-year analyses were described as descriptive. No approval decision should be inferred from conference durability alone. Cross-trial comparisons with other adjuvant regimens remain speculative.

JCO’s simultaneous publication (doi:10.1200/jco-26-00835) strengthens transparency, but confirmatory randomized evidence is still the gate for guideline and formulary change. Until Phase 3 reads out, the correct interpretation is sustained Phase 2b benefit, not practice-changing proof.

Implications for pharma teams

• RFS HR 0.51 and DMFS HR 0.411 at ~60 months favor intismeran plus Keytruda.
• ASCO 2026 featured 100+ Merck oncology abstracts across 25+ cancers.
• KEYNOTE-942 enrollment: 157 randomized patients (107 combination; 50 monotherapy).
• OS HR 0.471 remains exploratory; Phase 3 is the decision node.

Medical affairs teams should prepare dual narratives: Keytruda monotherapy remains the control backbone, while personalized neoantigen add-ons are investigational upside. Competitive intelligence should track manufacturing scale claims as closely as efficacy slides.

Related NovaPharma coverage

• FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer
• FDA Approves Keytruda for Adjuvant Treatment of Stage III Melanoma
• AACR 2026: Pembrolizumab and Moderna melanoma data

Frequently Asked Questions

Primary Sources

1. Merck/Moderna KEYNOTE-942 five-year ASCO 2026 release
2. Merck ASCO 2026 oncology portfolio highlights
3. ClinicalTrials.gov NCT03897881 (KEYNOTE-942)
4. Journal of Clinical Oncology KEYNOTE-942 5-year update (doi)